pharma · CDK Gene Mutation · Solid Tumor, Adult · KZIA
Kazia Therapeutics
KAZIA THERAPEUTICS LTD
Kazia Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 300 Barangaroo Ave, L24, Barangaroo, New South Wales 2000, AU
- Founded
- 2016
- Employees
- 15
- Programs
- 13
- Drugs
- 9
- Patents
- 1
Kazia Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Kazia Therapeutics.
Kazia Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Abemaciclib
KAZIA THERAPEUTICS LTD
CDK Gene Mutation
1 trial -
PAXALISIB
KAZIA THERAPEUTICS LTD
Primary Central Nervous System Lymphoma
1 trial -
Paxalisib
KAZIA THERAPEUTICS LTD
Malignant Primary Gliomas
1 trial -
Paxalisib
KAZIA THERAPEUTICS LTD
Glioblastoma
1 trial -
Paxalisib
KAZIA THERAPEUTICS LTD
Childhood Cancer
1 trial -
Paxalisib (GDC-0084)
KAZIA THERAPEUTICS LTD
Glioblastoma, Adult
1 trial -
Trastuzumab
KAZIA THERAPEUTICS LTD
Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Kazia Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.